Co-targeting the PI3K and MEK pathways in NSCLC: an in vitro evaluation and mutation prevalence in an Irish patient cohort

被引：0
|
作者：
Heavey, S. [1 ]
Barr, M. P. [1 ,2 ]
Hennessy, B. [3 ]
Toomey, S. [3 ]
Carr, A. [3 ]
Crown, J. [4 ]
Finn, S. [1 ]
Cuffe, S. [1 ,2 ]
O'Byrne, K. J. [5 ]
Gately, K. A. [1 ,2 ]
机构：
[1] Univ Dublin Trinity Coll, Dublin 2, Ireland
[2] St James Hosp, HOPE Directorate, Dublin 8, Ireland
[3] Royal Coll Surgeons Ireland, Dublin 2, Ireland
[4] St Vincents Hosp, Dublin 4, Ireland
[5] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
来源：
LUNG CANCER | 2014年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [21] Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo
    Posch, Christian
    Moslehi, Homayoun
    Feeney, Luzviminda
    Green, Gary A.
    Ebaee, Anoosheh
    Feichtenschlager, Valentin
    Chong, Kim
    Peng, Lily
    Dimon, Michelle T.
    Phillips, Thomas
    Daud, Adil I.
    McCalmont, Timothy H.
    LeBoit, Philip E.
    Ortiz-Urda, Susana
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (10) : 4015 - 4020
  • [22] Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma
    Xiaolin Peng
    Yao Liu
    Shan Zhu
    Xin Peng
    Hui Li
    Wenhui Jiao
    Peng Lin
    Zhe Zhang
    Yuling Qiu
    Meihua Jin
    Ran Wang
    Dexin Kong
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 2921 - 2936
  • [23] Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC
    Liao, Jipei
    Yang, Zejia
    Abarzarzin, Shirin
    Cullen, Kevin J.
    Dan, Hancai
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (05): : 1126 - 1135
  • [24] Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma
    Peng, Xiaolin
    Liu, Yao
    Zhu, Shan
    Peng, Xin
    Li, Hui
    Jiao, Wenhui
    Lin, Peng
    Zhang, Zhe
    Qiu, Yuling
    Jin, Meihua
    Wang, Ran
    Kong, Dexin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (12) : 2921 - 2936
  • [25] α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways
    R Tiwary
    W Yu
    B G Sanders
    K Kline
    British Journal of Cancer, 2011, 104 : 101 - 109
  • [26] In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC
    Heavey, Susan
    Cuffe, Sinead
    Finn, Stephen
    Young, Vincent
    Ryan, Ronan
    Nicholson, Siobhan
    Leonard, Niamh
    McVeigh, Niall
    Barr, Martin
    O'Byrne, Kenneth
    Gately, Kathy
    ONCOTARGET, 2016, 7 (48) : 79512 - 79529
  • [27] α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways
    Tiwary, R.
    Yu, W.
    Sanders, B. G.
    Kline, K.
    BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 101 - 109
  • [28] Effect of everolimus and gefitinib on PI3K/akt/mTOR and raf/MEK/ERK pathways in NSCLC cells.
    Dong, S.
    Zhang, X.
    Chang, H.
    Guo, A.
    Zhu, J.
    Yang, S.
    Wu, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Co-targeting BCL-2 and PI3K potently induces BAXdependent mitochondrial apoptosis in AML
    Grant, Steven
    Rahmani, Mohamed
    Nkwocha, Jewel
    Kmieciak, Maciej
    Leverson, Joel
    Sampath, Deepak
    CANCER RESEARCH, 2018, 78 (13)
  • [30] Targeting EGFR and PI3K pathways in ovarian cancer
    S Glaysher
    L M Bolton
    P Johnson
    N Atkey
    M Dyson
    C Torrance
    I A Cree
    British Journal of Cancer, 2013, 109 : 1786 - 1794
12345